Hypocholesterolaemia and cancer?
SIR,-The largest study so far was not mentioned in Dr K G Taylor's leading article (21 May, p 1598). In an international collaborative analysis,' which included a large UK centre, we found that the association with a low serum cholesterol concentration was not specific for colon cancer and that it was almost entirely short term. (table) . It seems that the main, and Mean difference in cholesterol concentrations and number of deaths Mean cholesterol difference (mmol/l) Period of follow up (years) All cancers Colon cancer 1 -0-75 (70) -0-65 (4) 2-5 -0-10 (616) -0-23 (41) 6-10 -0-05 (798) +0-08 (60) Conversion: SI to traditional units-Cholesterol: 1 mmol/l 38-7 mg/100 ml. Values in parentheses = number of deaths. possibly the whole, explanation of the association in many populations is the presence of an undetected cancer when the cholesterol concentration was measured.
GEOFFREY Influence of ranitidine on plasma metoprolol concentrations SIR,-In man metoprolol is oxidised in the liver by the cytochrome P450-linked mixed function oxygenase enzyme system (P450 oxygenase), and as much as 97 % ofthe ingested drug may be excreted in the urine as oxidation products.' Accordingly, if the increases in the peak plasma concentration and plasma half life of the drug reported by Dr H Spahn and others (14 May, p 1546) in patients treated with ranitidine are real, the primary cause must be ranitidine induced inhibition of the P450 oxygenase concerned. Their implication that reduced liver blood flow caused by ranitidine might also be a contributory factor cannot be right because such a reduction would tend to increase rather than to decrease the degree of first pass metabolism of the drug. In any event, the available evidence shows ranitidine to have little effect on liver blood flow.2
In view of the quality of published evidence to the contrary,3 it is difficult to accept readily that ranitidine appreciably inhibits P450 oxygenase. Indeed, there is much published work showing its lack of effect on the metabolism or disposition in man of numerous drugs known to be processed by the enzyme; these include propranolol, lignocaine, warfarin, diazepam, theophylline, phenytoin, and antipyrine. Furthermore, Hoensch and Hetzel,5 whose results are wrongly interpreted by Dr Spahn and others, confirmed the report by Knodell et a16 that cimetidine, but not ranitidine, gave a type II binding spectrum with human P450 oxygenase. They also reported Ki (inhibitor constant) values for cimetidine (2-5 mM) and ranitidine (8-7 mM) for the enzyme which are consistent with Knodell's finding that cimetidine (2-94 mM), but not ranitidine (2-86 mM), inhibited the demethylation of pethidine and the hydroxylation of pentobarbital by human liver microsomes in vitro. The evidence that ranitidine is qualitatively different from cimetidine in not inhibiting P450 oxygenase in man is, therefore, strong.
If the observations of Dr Spahn and others are correct, they may be explained in two ways. Firstly, metoprolol may be metabolised by a subtype of P450 oxygenase which is inhibited by ranitidine but is not concerned in the metabolism of the other known substrates of the enzyme. Apart from the work of Dr Spahn and others, there is no evidence in favour of this proposal.The second explanation depends on the known high variability between subjects of the pharmacokinetic parameters for metoprolol and the knowledge that they are affected by a number of factors, including diet and posture.7 The relatively small effects reported by Dr Spahn and others could easily have resulted from such factors if the study was less than perfectly controlled.
It is, of course, possible that the results of Dr Spahn and others are not correct, perhaps because of statistical chance. Indeed, this possibility is consistent with their observation that ranitidine plus metoprolol had no greater effect on tachycardia induced by exercise than metoprolol alone. Their explanation that metoprolol, 100 mg twice daily by mouth, caused near maximal inhibition of the tachycardia is at odds with the known dose response relations for the drug.8 9
In view of its variable fate in man metoprolol is not the most suitable substance for assessing drug induced inhibition of P450 oxygenase. Because of this and for the other reasons given, we think it premature to conclude on the basis of the evidence of Dr Spahn and others that ranitidine has an appreciable action on oxidative metabolism of drugs by this enzyme system. D JACK M MITCHARD R N SMITH Erythrocyte ferritin content in idiopathic haemochromatosis and alcoholic liver disease with iron overload SIR,-We would like to comment on certain points raised by Dr M B Van der Weyden and others (5 March, p 752). Firstly, the authors refer to a previous article by Porter' for the serum ferritin assay method. The method described by Porter is based on a spleen ferritin inhibition type radioimmunoassay. We wonder whether Dr Van der Weyden and others used this type of assay for serum ferritin rather than the hepatic ferritin radioimmunoassay (Gammadab ferritin radioimmunoassay, Clinical Assays), which they used to determine the erythrocyte ferritin content.
Furthermore, Ccok et al and Lipschitz et al2 3 have shown that serum concentrations of ferritin and formed blood elements such as erythrocytes, granulocytes, and mononuclear cells are distributed lognormally. Obviously, the Student's t test is not suitable for comparing two such distributions unless statistical analysis is performed after logarithmic transformation of the data; it is not clear whether this was done by Dr Van der Weyden and others. Because of the lognormal distribution, erythrocyte and serum ferritin concentrations of a population should preferably be expressed as the median with log 95% confidence limits (or median and range) rather than simply as mean ± 1 (or 2) standard deviation(s).4
We have some doubt about the value of the erythrocyte to serum ferritin ratio as discriminant on an individual basis. Using a previously described method for the separation of blood cells3 we measured ferritin content in the different cell fractions with the same method as that used by Dr Van der Weyden and others for erythrocyte ferritin assay (Gammadab ferritin radioimmunoassay, Clinical Assays). Our results, although persistently higher due to the method of calibration in the assay, correlated well with those of Lip-schitz3 for all cell fractions described (r= 0-99). We found a median erythrocyte ferritin content of 0-015 fg/cell, with a range from 0-006 to 0-036 fg/ cell (95% confidence limits: 0004-0.054) for healthy volunteers (n= 12) and a median erythrocyte ferritin content of 0-008 fg/cell, ranging from 0 004 to 0-041 fg/cell, in healthy male blood donors (n= 6) (more than 10 donations) (95% confidence limits: 0-001-0-043). The median ratio of erythrocyte to serum ferritin for all members of these two groups was 0-16 (range: 0.07-0.82) for normal controls and 0-33 (range: 0-08-1-09) in blood donors. The range of the ratio shows a wide distribution. No significant correlation could be found between serum ferritin concentrations and erythrocyte ferritin content (normal subjects, r=0 07; blood donors, r-=0 46). Moreover, the normal range for serum ferritin is known to be different for normal men and for normal premenopausal women. In contrast, no significant difference in blood cell ferritin content was reported for these two groups.5
Hence, a significant difference between men and premenopausal women is to be expected
